IN8bio reports Q4 2024 net loss $6.2M; cash $11.1M as of Dec 31; clinical updates on INB-100/200/400

IN8BIO, INC.

Net loss Q4 2024 $6.2M ($0.08/share) vs $7.6M ($0.22/share) in Q4 2023; full-year net loss $30.4M vs $30.0M.
Cash $11.1M as of Dec 31, 2024; plus $4.1M net proceeds from ATM/warrant exercises in Feb 2025, extending runway into March 2026.
INB-100 Phase 1: 100% of treated AML patients relapse-free as of Jan 17, 2025; no CRS/ICANS; enrollment expansion ongoing.
INB-200: majority of patients exceeded expected PFS; one IDH-mutant patient progression-free for 40.5 months as of Oct 2024.
INB-400 Phase 2 enrollment paused; seeking partnerships; introduced INB-600 platform (INB-619 TCE targeting CD19) with preclinical data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.